Tevogen Bio Announces Positive Proof-of-Concept Clinical Trial Results of Its Off-The-Shelf, Allogeneic Cytotoxic CD8+ T Cell Therapy for Treatment of Acute High-Risk COVID Patients, First Clinical Product of Company’s Precision Cell Therapy Platform
Tevogen Bio to Study Potential Use of its T cell Technology in Epstein-Barr Virus and Multiple Sclerosis
Tevogen Bio to Study Therapeutic Potential of its Investigational COVID-19 T Cell Therapy in Long COVID
Latest News
Tevogen Bio Expresses Gratitude as CEO is Named Recipient of Boy Scouts of America Distinguished Citizen Award
Tevogen Bio – May 11th, 2023
Tevogen Bio CSO to Discuss Investigational T Cell Therapy at NOLA Conference Focused on Long COVID and COVID-Related Cancer Risk, Alongside Leading Oncology Experts
Tevogen Bio – April 26th, 2023
Tevogen Bio Announces Positive Proof-of-Concept Clinical Trial Results of Its Off-The-Shelf, Allogeneic Cytotoxic CD8+ T Cell Therapy for Treatment of Acute High-Risk COVID Patients, First Clinical Product of Company’s Precision Cell Therapy Platform
Tevogen Bio – January 23rd, 2023
Tevogen Bio to Study its Investigational COVID-19 T Cell Therapy in Immunocompromised Patients Who are Unable to Benefit From Currently Available Prevention or Treatment Options
Tevogen Bio – December 7th, 2022
Tevogen Bio to Develop T Cell Therapies for Treatment of Epstein-Barr Virus Related Cancers and Multiple Sclerosis
Tevogen Bio – December 1st, 2022
Tevogen Bio to Study Therapeutic Potential of its Investigational COVID-19 T Cell Therapy in Long COVID
Tevogen Bio – November 22nd, 2022
Tevogen Bio CEO Dr. Ryan Saadi and Chief Scientific Officer Dr. Neal Flomenberg share White House concerns about emerging COVID-19 variants and their impact on immunocompromised patients, and express the company’s commitment to accelerate development of its investigational COVID-19 therapy
Tevogen Bio – October 27th, 2022
Tevogen Bio Expresses Gratitude for 2023 Nobel Peace Prize Nomination of the Company and its Founding CEO Ryan Saadi in Recognition of its Novel Business Model to Alleviate Health Inequality
Tevogen Bio – October 12th, 2022
Warren-based biotechnology company Tevogen Bio, CEO nominated for 2023 Nobel Peace Prize
ROI-NJ – October 6th, 2022
Tevogen Bio Appoints Esteemed Global Safety Management Expert Victor Sordillo to its Corporate Advisory Board
Tevogen Bio – August 31st, 2022
Tevogen Bio Appoints Three Prominent Healthcare Leaders to its Board of Directors
Tevogen Bio – August 17th, 2022
Tevogen Bio Announces Positive Safety Results Upon Completion of Patient Enrollment in Proof-of-Concept Clinical Trial of T cell Therapy for Elderly or High-Risk COVID-19 Patients
Tevogen Bio – August 1st, 2022
Tevogen Bio Appoints Acclaimed Oncologist and Immunotherapy Expert Neal Flomenberg, M.D. as Chief Scientific Officer and Global Head of R&D
Tevogen Bio – July 7th, 2022
Tevogen Bio Establishes Philadelphia R&D Center to Expedite Product Development in Oncology, Neurology, and Virology
Tevogen Bio – June 30th, 2022
Tevogen Bio Appoints Distinguished Clinician and Former Matheny President and CEO, Dr. Kendell R. Sprott, to Corporate Advisory Board
Tevogen Bio – June 23rd, 2022
Ryan Saadi’s Commencement Speech at Washington University of Science and Technology
Tevogen Bio – June 21st, 2022
Tevogen Bio Initiates Final Dose Level in Proof-of-Concept Clinical Trial of its Investigational T cell Therapy for High-Risk COVID-19 Patients
Tevogen Bio – June 7th, 2022
Tevogen Bio Expands Research and Development Capacity at CIC Philadelphia to Accommodate its Expanding Product Portfolio
Tevogen Bio – May 3rd, 2022
Tevogen Bio Expands Executive Leadership Team to Accelerate Operational Growth and Commercial Readiness
Tevogen Bio – April 5th, 2022
Tevogen Bio™ Appoints Prominent Industry Leader Susan Podlogar to the Company’s Corporate Advisory Board
Tevogen Bio – March 2nd, 2022
Tevogen Bio Accelerates Growth With New Corporate Hub to Accommodate its Expanding Operations
Tevogen Bio – February 7th, 2022
Tevogen Bio Announces Positive Safety Data from Second Cohort in Ongoing Proof-of-Concept Clinical Trial of TVGN-489, its Investigational T cell Therapy for Treatment of COVID-19 in High-Risk Patients
Tevogen Bio – February 3rd, 2022
SPH Dean’s next venture to drive down treatment costs
Yale Daily News – January 26th, 2022
Tevogen Bio to Study Potential Use of its T cell Technology in Epstein-Barr Virus and Multiple Sclerosis
Tevogen Bio – January 20th, 2022
Tevogen Bio Further Strengthens IP Portfolio With Additional Patent for Method of Preparing Its Investigational SARS-CoV-2 Specific T cell Therapy
Tevogen Bio – January 12th, 2022
Tevogen Bio Appoints Yale Public Health Dean Dr. Sten H. Vermund, Preeminent Global Expert in COVID-19 and Infectious Disease Epidemiology, to its Innovation and Public Health Advisory Council
Tevogen Bio – January 5th, 2022
Tevogen Bio Reinforces IP Portfolio With Additional US Patent for Its Investigational T Cell Therapy for Treatment of COVID-19
Businesswire – December 29th, 2021
Tevogen Bio Presents Data Detailing Immunologic Escape in SARS-CoV-2 Variants Underscoring Criticality of its T Cell Target Tuning Technology and Investigational COVID-19 therapy at ASH 2021
Businesswire – December 14th, 2021
Tevogen Bio Announces U.S. Patent and Trademark Office Has Granted Patent for Preparation of Tevogen’s SARS-CoV-2 Specific Allogeneic Cytotoxic T Lymphocytes (CTL) and Methods of Treatment Using Tevogen’s Investigational CTL Therapy for COVID-19
Businesswire – December 8th, 2021
Dr. Lindee Goh of Tapestry Networks and Jeffrey Feike, President and Chief Administrative Officer of Fort Loudoun Medical Center, Join Tevogen Bio’s Innovation and Public Health Advisory Council
Businesswire – December 6th, 2021
SHARED@Yale Roundtable Explores Health Care in the Era of COVID-19
Yale School of Public Health – December 6th, 2021
Tevogen Bio Announces its Investigational SARS-CoV-2 Specific T cell Therapy, TVGN-489, Is Not Affected by Omicron Variant Following Research Team Review of all Reported Mutations
Businesswire – December 2nd, 2021
FDA OK’s next phase for Jefferson University’s new COVID-19 treatment
6ABC News – November 29th, 2021
SHARED@Yale: Inaugural Roundtable on Post-COVID Health Care Announced
Yale School of Public Health – November 22nd, 2021
Tevogen Bio Announces First Cohort Dosed in Ongoing Proof of Concept Clinical Trial of TVGN-489, its Investigational T cell Immunotherapy Product for Treatment of COVID-19 in High-Risk Patients
Businesswire – November 16th, 2021
Tevogen Bio CEO Dr. Ryan Saadi Appointed to Yale School of Public Health Leadership Council
Businesswire – October 27th, 2021
A Pandemic Silver Lining: Why Now is our Opportunity to Disrupt the Flawed U.S. Health Care System
Yale School of Public Health – October 8th, 2021
Tevogen Bio Reaches Major Milestone in Commercial Manufacturing Readiness by Completing the Technology Transfer of its Investigational COVID-19 T Cell Therapy
Businesswire – September 9th, 2021
Tevogen Bio to Initiate Clinical Trial of its Investigational T Cell Therapy for COVID-19 at Thomas Jefferson University
Businesswire – September 1st, 2021
Tevogen Bio Revolutionizing Healthcare through an Innovative Public Health Centric Model
Pharma Tech Outlook – August 30th, 2021
Tevogen Bio Partners with Yale School of Public Health to Prepare Tomorrow’s Leaders in Regulatory Science
Businesswire – July 14th, 2021
Tevogen Bio Announces FDA Clearance of Investigational New Drug (IND) Application For its Cytotoxic T Cell Therapy for COVID-19
Businesswire – July 12th, 2021
Tevogen Bio’s TVGN-489, an Allogeneic SARS-CoV-2 Specific Cytotoxic T Cell Therapy, Demonstrates Strong Anti-Viral Activity in Preclinical Study, as Presented by Professor Neal Flomenberg of Thomas Jefferson University
Businesswire – May 11th, 2021
Tevogen Bio to Present Preclinical Data of TVGN-489, its Investigational Allogeneic Cytotoxic T Cell Therapy for COVID-19, at the 2021 Annual Meeting of American Association of Immunologists
Businesswire – April 12th, 2021
Tevogen CEO Ryan Saadi, MD, MPH, sat down with Cell & Gene Editor-In-Chief Erin Harris to discuss why T Cell therapy could be a potential game changer for COVID-19.
Cell & Gene – March 23rd, 2021
Tevogen Bio Announces Partnership With BioCentriq, New Jersey Innovation Institute’s Pioneering Cell and Gene Therapy Center, to Enhance Tevogen’s Development Capacity of Its Proprietary Targeted T Cell Therapy For COVID-19
Businesswire – March 15th, 2021
Tevogen Bio Secures Funding from Team of Doctors to Support Clinical Trials of Its Investigational Curative T Cell Therapy for COVID-19
Newswire – January 25th, 2021
Tevogen Bio Announces IND Submitted to FDA for Clinical Trials of T Cell Treatment for COVID-19
Newswire – October 14th, 2020
Dr. Flomenberg discusses T Cell therapy for COVID-19 with 6ABC News.
6ABC – August 20th, 2020
Tevogen Bio Announces Partnership With Preeminent Scientist Professor Neal Flomenberg, M.D., to Investigate Proprietary T-Cell Therapy for Treatment of COVID-19 & Influenza
Newswire – August 10th, 2020
Tevogen Bio Announces Steps Toward a Proprietary T Cell Therapy for Treatment of COVID-19 & Development of Bivalent Vaccine for COVID-19 & Influenza
Newswire – July 15th, 2020
Tevogen Corporate Office – Warren, New Jersey
Presenting the Future Research and Manufacturing Facility of Tevogen Bio
Tevogen Bio is pleased to finalize the design of its state-of-the-art, eco-friendly research and manufacturing facility to accommodate its anticipated growth. This planned facility will serve as the company’s central hub for research, manufacturing, and distribution. Congratulations to our team of visionary architects and lab engineers!
Social Media
© 2023 Tevogen Bio. All Rights Reserved.